Education Information: Cardiff achieves ‘Champion’ status for gender equality in physics  |  Parent Interventions: Online survey to assess needs of children and young people with cancer   |  Parent Interventions: Study links severe childhood deprivation to difficulties in adulthood  |  Parent Interventions: New study aims to learn the lessons of homeschooling  |  Teacher Insights: Using e-learning to raise biosecurity awareness  |  National Edu News: Science and Technology in finding solutions to combat COVID-19  |  National Edu News: Ek Bharat Shreshtha Bharat programme  |  Health Monitor: Beware of Hepatitis D, It can Lead to Hepatocellular Carcinoma  |  Teacher Insights: Education project to understand Birmingham learning at home during COVID-19  |  Education Information: UoG launches new onlines to meet some of the challenges of Covid-19  |  Teacher Insights: Professor Woolfson awarded Humboldt Research Prize  |  Parent Interventions: Parents paying heavy price for lockdown  |  Teacher Insights: Great Science Share brings science investigations into homes  |  Education Information: App will reduce high risk of falls during and after Lockdown  |  Education Information: University of Manchester to decarbonise its investment portfolio  |  
May 09, 2020 Saturday 09:23:19 PM IST

A project to develop human monoclonal antibodies gets approval

Science Innovations

Given the importance of deploying multiple strategies against Covid-19, CSIR through NMITLI program has approved a project towards development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. This project on generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team. The team comprises of academic institutes and industry with participants from NCCS, IIT-Indore, PredOmix Technologies Pvt. Ltd. and Bharat Biotech International Ltd (BBIL).

The project aims to generate hmAbs to SARS-CoV-2 from convalescent phase of COVID-19 patients and select high affinity and neutralizing antibodies. The project also aims to anticipate future adaptation of the virus and generate hmAbs clones that can neutralize the mutated virus so that could be readily used for combating future SARS-CoV infections.BBIL will be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.

Comments